Quarterly ResultMay 7, 2026, 07:22 AM
Scholar Rock Q1 Net Loss $(105.5)M; Apitegromab BLA PDUFA Sep 30, 2026
AI Summary
Scholar Rock Holding Corp. reported a net loss of $105.5 million for the first quarter of 2026, an increase from $74.7 million in Q1 2025, primarily due to higher operating expenses. The company significantly bolstered its cash position to $430.5 million, driven by $98.0 million from common share sales and $196.7 million from a new debt facility. The Biologics License Application (BLA) for apitegromab was resubmitted in March 2026, with a Prescription Drug User Fee Act (PDUFA) action date set for September 30, 2026. Scholar Rock anticipates its current cash resources will fund operations for at least one year.
Key Highlights
- Net loss increased to $(105.5) million in Q1 2026 from $(74.7) million in Q1 2025.
- Net loss per share was $(0.83) in Q1 2026, up from $(0.67) in Q1 2025.
- Cash and cash equivalents rose to $430.5 million as of March 31, 2026.
- Proceeds from common share sales totaled $98.0 million in Q1 2026.
- Proceeds from a new debt facility were $196.7 million in Q1 2026.
- Apitegromab BLA resubmitted in March 2026 with PDUFA date of September 30, 2026.
- R&D expenses increased to $51.8 million in Q1 2026 from $48.7 million in Q1 2025.
- G&A expenses rose to $50.2 million in Q1 2026 from $28.4 million in Q1 2025.
Price Impact
More from SRRK